3 Things In Biotech, March 8: A Tale Of 3 New Trials


Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: SGEN announced that it initiated a phase 1 clinical study to assess the safety and tolerability of its CD48-directed antibody-drug conjugate SGN-CD48A in patients with relapsed/refractory multiple myeloma.



from Biotech News